BNT-162b2 and mRNA-1273 achieve only partial cross-neutralization of novel SARS-CoV-2 variants April 14, 2021
Merck & Co. presents a novel potent, selective and brain-penetrant LRRK2 kinase inhibitor April 14, 2021